PALI

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation oral PDE4 inhibitor prodrugs for the treatment of inflammatory and fibrotic diseases. Its lead product, PALI-2108, is designed to selectively target PDE4 inhibition in the ileum and colon, facilitating systemic distribution of the active drug. The company is advancing PALI-2108 through Phase 2 clinical trials for conditions such as ulcerative colitis and Crohn's disease, primarily serving patients with chronic inflammatory bowel diseases. Palisade Bio operates from Denver, Colorado.